Peripheral Nerve Regenerative Interface for Neuroma
(NBxPilot Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding a treatment called Regenerative Peripheral Nerve Interface (RPNI) during sural nerve biopsies can prevent painful nerve problems known as neuromas. Neuromas can cause discomfort and sometimes require additional surgeries, so preventing them could improve patient care and quality of life. Participants are divided into two groups: one group will undergo only the biopsy, while the other will receive both the biopsy and the RPNI treatment. This trial is suitable for individuals referred for sural nerve and muscle biopsy at the University of British Columbia, provided they have not had previous nerve injuries or surgeries.
As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance future patient care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the regenerative peripheral nerve interface (RPNI) is safe for use in sural nerve biopsy?
Research has shown that the Regenerative Peripheral Nerve Interface (RPNI) is generally well-tolerated by patients and significantly reduces pain. For example, one study reported a 71% decrease in neuroma pain, a type of nerve pain, and a 53% reduction in phantom pain, the pain felt where a limb has been amputated. Another review found that RPNI can effectively prevent painful neuromas from forming and reduce phantom limb pain. These findings suggest that RPNI is safe, with many patients experiencing less pain after treatment.12345
Why are researchers excited about this trial?
Researchers are excited about the Peripheral Nerve Regenerative Interface (RPNI) for treating neuromas because it offers a novel approach to nerve repair. Unlike traditional treatments, which may involve pain management or surgical removal of the neuroma, RPNI aims to regenerate nerve tissue by using a patient's own muscle grafts to create a biological interface. This method could potentially restore nerve function and reduce pain more effectively. By focusing on nerve regeneration, RPNI presents a promising alternative that could lead to improved outcomes for patients suffering from neuromas.
What evidence suggests that the Peripheral Nerve Regenerative Interface is effective for reducing symptomatic neuroma formation?
Research has shown that the Regenerative Peripheral Nerve Interface (RPNI) effectively reduces pain from neuromas, which are painful nerve growths. In one study with 45 patients who underwent RPNI, none developed neuromas, and only about half experienced phantom limb pain. This method helps nerves reconnect properly, reducing pain. A review of several studies also found that RPNI reduces phantom and residual limb pain more effectively than standard treatments. In this trial, some participants will undergo RPNI during their sural nerve and muscle biopsy, while others will have the biopsy alone. Overall, RPNI surgery can lessen physical pain and improve patients' quality of life.13456
Who Is on the Research Team?
Jenna-Lynn Senger, MD
Principal Investigator
University of British Columbia
Are You a Good Fit for This Trial?
This trial is for individuals who are undergoing sural nerve biopsy due to conditions like neuroma, including Morton's Neuroma. The study aims to see if a special surgical technique called RPNI can prevent painful nerve growths after the biopsy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo sural nerve and muscle biopsy, with or without RPNI
Follow-up
Participants are monitored for symptomatic neuroma formation and changes in pain and sensation
What Are the Treatments Tested in This Trial?
Interventions
- Peripheral Nerve Regenerative Interface (RPNI)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor